IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0574631
(2004-10-21)
|
등록번호 |
US-7407973
(2008-08-05)
|
국제출원번호 |
PCT/US04/035390
(2004-10-21)
|
§371/§102 date |
20070131
(20070131)
|
국제공개번호 |
WO05/040758
(2005-05-06)
|
발명자
/ 주소 |
- Ozes,Osman N.
- Blatt,Lawrence M.
- Seiwert,Scott D.
|
출원인 / 주소 |
|
대리인 / 주소 |
Marshall, Gerstein & Borun LLP
|
인용정보 |
피인용 횟수 :
25 인용 특허 :
91 |
초록
▼
The present invention provides methods for treating a disorder, and methods for inhibiting a stress-activated protein kinase (SAPK) in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; c
The present invention provides methods for treating a disorder, and methods for inhibiting a stress-activated protein kinase (SAPK) in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; comparing a post-treatment SAPK activity level in a biological sample from the individual with a pre-treatment SAPK activity level; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step. The present invention provides methods for treating a disorder, and methods for inhibiting a SAPK in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; comparing a second post-treatment SAPK activity level in a biological sample from the individual with a first post-treatment SAPK activity level; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step.
대표청구항
▼
What is claimed is: 1. A method of treating a disorder in an individual, the method comprising administering to an individual who has the disorder an effective amount of pirfenidone or a pirfenidone analog; comparing a post-treatment level of stress-activated protein kinase (SAPK) activity in a bio
What is claimed is: 1. A method of treating a disorder in an individual, the method comprising administering to an individual who has the disorder an effective amount of pirfenidone or a pirfenidone analog; comparing a post-treatment level of stress-activated protein kinase (SAPK) activity in a biological sample from the individual to a pre-treatment level of SAPK activity; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step; wherein the disorder is selected from the group consisting of fibrotic disorder, carcinoma, sarcoma, leukemia, lymphoma, viral infection, inflammatory disorder and TNF-mediated disorder, and wherein said carcinoma is selected from the group consisting of esophageal carcinoma, hepatocellular carcinoma, basal cell carcinoma, bladder carcinoma, including transitional cell carcinoma which is a malignant neoplasm of the bladder, squamous cell carcinoma, bronchogenic carcinoma, colon carcinoma, colorectal carcinoma, gastric carcinoma, lung carcinoma, including small cell carcinoma and non-small cell carcinoma of the lung, adrenocortical carcinoma, thyroid carcinoma, pancreatic carcinoma, breast carcinoma, ovarian carcinoma, prostate carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, renal cell carcinoma, ductal carcinoma in situ or bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical carcinoma, uterine carcinoma, testicular carcinoma, osteogenic carcinoma, epithelieal carcinoma, and nasopharyngeal carcinoma. 2. The method of claim 1, wherein the post-treatment SAPK activity level is from about 10% to about 40% lower than the pre-treatment SAPK activity level, and wherein the adjusting step comprises administering a second dosage of pirfenidone or pirfenidone analog that is at least about 10% higher than the first dosage of pirfenidone or pirfenidone analog. 3. The method of claim 1, wherein the biological sample is peripheral blood mononuclear cells. 4. The method of claim 1, wherein said fibrotic disorder is pulmonary fibrosis, renal fibrosis, liver fibrosis, or heart fibrosis. 5. The method of claim 1, further comprising administering an effective amount of a Type II interferon receptor agonist. 6. The method of claim 5, wherein the Type II interferon receptor agonist is IFN-γ. 7. The method of claim 1, further comprising administering an effective amount of a Type I interferon receptor agonist. 8. The method of claim 7, wherein the Type I interferon receptor agonist is IFN-α. 9. A method of treating a disorder in an individual, the method comprising administering to an individual who has the disorder an effective amount of pirfenidone or a pirfenidone analog; comparing a second post-treatment level of stress-activated protein kinase (SAPK) activity in a biological sample from the individual to a first post-treatment level of SAPK activity; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step; wherein the disorder is selected from the group consisting of fibrotic disorder, carcinoma, sarcoma, leukemia, lymphoma, viral infection, inflammatory disorder and TNF-mediated disorder, and wherein said carcinoma is selected from the group consisting of esophageal carcinoma, hepatocellular carcinoma, basal cell carcinoma, bladder carcinoma, including transitional cell carcinoma which is a malignant neoplasm of the bladder, squamous cell carcinoma, bronchogenic carcinoma, colon carcinoma, colorectal carcinoma, gastric carcinoma, lung carcinoma, including small cell carcinoma and non-small cell carcinoma of the lung, adrenocortical carcinoma, thyroid carcinoma, pancreatic carcinoma, breast carcinoma, ovarian carcinoma, prostate carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, renal cell carcinoma, ductal carcinoma in situ or bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical carcinoma, uterine carcinoma, testicular carcinoma, osteogenic carcinoma, epithelieal carcinoma, and nasopharyngeal carcinoma. 10. A method of inhibiting a stress-activated protein kinase enzymatic activity in a cell of an individual, the method comprising administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; comparing a post-treatment level of stress-activated protein kinase (SAPK) activity in a biological sample from the individual to a pre-treatment level of SAPK activity; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step: wherein the individual in need thereof has a disorder selected from the group consisting of fibrotic disorder, carcinoma, sarcoma, leukemia, lymphoma, viral infection, inflammatory disorder and TNF-mediated disorder, and wherein said carcinoma is selected from the group consisting of esophageal carcinoma, hepatocellular carcinoma, basal cell carcinoma, bladder carcinoma, including transitional cell carcinoma which is a malignant neoplasm of the bladder, squamous cell carcinoma, bronchogenic carcinoma, colon carcinoma, colorectal carcinoma, gastric carcinoma, lung carcinoma, including small cell carcinoma and non-small cell carcinoma of the lung, adrenocortical carcinoma, thyroid carcinoma, pancreatic carcinoma, breast carcinoma, ovarian carcinoma, prostate carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, renal cell carcinoma, ductal carcinoma in situ or bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical carcinoma, uterine carcinoma, testicular carcinoma, osteogenic carcinoma, epithelieal carcinoma, and nasopharyngeal carcinoma. 11. The method of claim 1, wherein the carcinoma comprises a solid tumor. 12. The method of claim 1, wherein the sarcoma comprises a solid tumor. 13. The method of claim 1, wherein the leukemia comprises a solid tumor. 14. The method of claim 1, wherein the lymphoma comprises a solid tumor. 15. The method of claim 11, wherein the pirfenidone or pirfenidone analog are administered as adjuvant therapy to a primary carcinoma therapy. 16. The method of claim 12, wherein the pirfenidone or pirfenidone analog are administered as adjuvant therapy to a primary sarcoma therapy. 17. The method of claim 13, wherein the pirfenidone or pirfenidone analog are administered as adjuvant therapy to a primary leukemia therapy. 18. The method of claim 14, wherein the pirfenidone or pirfenidone analog are administered as adjuvant therapy to a primary lymphoma therapy.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.